Sec Form 4 Filing - GLAXOSMITHKLINE PLC @ CVRx, Inc. - 2021-07-02

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person GLAXOSMITHKLINE PLC 2. Issuer Name and Ticker or Trading Symbol CVRx, Inc. [ CVRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 980 GREAT WEST ROAD 3. Date of Earliest Transaction (MM/DD/YY) 07/02/2021 (Street) BRENTFORD MIDDLESEX, X0TW8 9GS 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/02/2021 C 1,505 A 33,316 I See Footnote ( 4 ) Common Stock 07/02/2021 C 12,979 A 46,295 I See Footnote ( 4 ) Common Stock 07/02/2021 C 14,917 A 61,212 I See Footnote ( 4 ) Common Stock 07/02/2021 C 8,380 A 69,592 I See Footnote ( 4 ) Common Stock 07/02/2021 C 27,345 A 96,937 I See Footnote ( 4 ) Common Stock 07/02/2021 C 635,646 A 732,583 I See Footnote ( 4 ) Common Stock 07/02/2021 P( 1 ) 275,000 A $ 18 1,007,583 I See Footnote ( 5 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series B-2 Preferred Stock ( 2 ) 07/02/2021 C 59,527 ( 2 ) ( 2 ) Common Stock 1,505 $ 0 0 I See Footnote ( 4 ) Series C-2 Preferred Stock ( 2 ) 07/02/2021 C 513,312 ( 2 ) ( 2 ) Common Stock 12,979 $ 0 0 I See Footnote ( 4 ) Series D-2 Preferred Stock ( 2 ) 07/02/2021 C 589,939 ( 2 ) ( 2 ) Common Stock 14,917 $ 0 0 I See Footnote ( 4 ) Series E-2 Preferred Stock ( 2 ) 07/02/2021 C 331,399 ( 2 ) ( 2 ) Common Stock 8,380 $ 0 0 I See Footnote ( 4 ) Series F-2 Preferred Stock ( 2 ) 07/02/2021 C 1,081,434 ( 2 ) ( 2 ) Common Stock 27,345 $ 0 0 I See Footnote ( 4 ) Series G Preferred Stock ( 3 ) 07/02/2021 C 10,055,408 ( 3 ) ( 3 ) Common Stock 635,646 $ 0 0 I See Footnote ( 4 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRENTFORD MIDDLESEX, X0TW8 9GS X Signatures /s/ Victoria Whyte 07/06/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Glaxo Group Limited acquired 275,000 Common Stock of the Issuer in connection with the Issuer's initial public offering. ( 2 )The Series B-2 Preferred Stock, Series C-2 Preferred Stock, Series D-2 Preferred Stock, Series E-2 Preferred Stock and Series F-2 Preferred Stock automatically converted into common stock on a 1-for-0.025857287 basis (in each case, subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. ( 3 )The Series G Preferred Stock automatically converted into common stock on a 1-for-0.0632143218 basis (subject to the payment of cash in lieu of any fractional shares) without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. ( 4 )The shares reported herein are held of record by Action Potential Venture Capital Limited, an indirect, wholly owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). ( 5 )The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of the Reporting Person.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.